ATC Abstracts

American Transplant Congress abstracts

  • Home
  • Meetings Archive
    • 2022 American Transplant Congress
    • 2021 American Transplant Congress
    • 2020 American Transplant Congress
    • 2019 American Transplant Congress
    • 2018 American Transplant Congress
    • 2017 American Transplant Congress
    • 2016 American Transplant Congress
    • 2015 American Transplant Congress
    • 2013 American Transplant Congress
  • Keyword Index
  • Resources
    • 2021 Resources
    • 2016 Resources
      • 2016 Welcome Letter
      • ATC 2016 Program Planning Committees
      • ASTS Council 2015-2016
      • AST Board of Directors 2015-2016
    • 2015 Resources
      • 2015 Welcome Letter
      • ATC 2015 Program Planning Committees
      • ASTS Council 2014-2015
      • AST Board of Directors 2014-2015
      • 2015 Conference Schedule
  • Search

Articles tagged "Hepatocellular carcinoma"

  • 2022 American Transplant Congress

    The Effect of Adoption of Acuity Circles on Hepatocellular Carcinoma Transplantation Rates at a Single High Acuity Center

    D. W. Victor III, J. Corkrean, S. Kodali

    Sherrie and Allan Conover Center for Liver disease and Transplantation, Houston Methodist Hospital, Houston, TX

    *Purpose: Transplantation for selected patient with HCC has been prioritized with a MELD exception since 2002. Further changes have decreased the maximum exception for HCC.…
  • 2022 American Transplant Congress

    Center-Level Variability in DDLT Rate Before and After the Implementation of MMaT/250 Score

    T. Ishaque, J. Beckett, B. King, J. G. Wang, D. Segev, A. Massie

    Johns Hopkins Medical Institutions, Baltimore, MD

    *Purpose: In 02/2020, OPTN replaced DSA/regional boundaries with acuity circles and substituted exception scores for individual patients to median-MELD-at-transplant within 250 nautical miles of a…
  • 2022 American Transplant Congress

    Cell-free Amniotic Fluid Reduces Liver Inflammation And Fibrosis

    F. Ditmars1, C. Bowen1, N. Liu1, K. L. Pereira de Castro1, J. Johnson1, M. Kueht1, A. Saad2, H. L. Stevenson3, J. Fair1, W. S. Fagg1

    1Surgery, University of Texas Medical Branch, Galveston, TX, 2Obstetrics and Gynecology, University of Texas Medical Branch, Galveston, TX, 3Pathology, University of Texas Medical Branch, Galveston, TX

    *Purpose: Effective interventions for hepatic inflammation and fibrosis remain a dire unmet need in transplant medicine. Cell-free amniotic fluid (AF) represents a potential alternative to…
  • 2022 American Transplant Congress

    Locoregional Therapy and Long-Term Post-Transplant Outcomes for HCC Liver Transplant Recipients

    T. Ishaque, S. R. Weeks, A. Kolarich, J. Ruck, J. Garonzik-Wang, D. Segev, A. Massie, B. King

    Johns Hopkins Medical Institutions, Baltimore, MD

    *Purpose: In last decade, locoregional therapy (LRT) have been widely used to downstage HCC patients in order to qualify for liver transplantation. Large-scale direct comparisons…
  • 2022 American Transplant Congress

    Degree of Pre-Liver Transplant Immune Dysfunction Correlates with Post-Transplant Cancer Recurrence

    G. S. Prakash1, G. G. Panayotova1, S. Simonishvili1, Y. Qin1, L. Jin1, T. Ayorinde1, L. J. Minze2, F. Paterno1, L. Brown1, A. Amin1, D. Liu1, R. Ghobrial2, J. V. Guarrera1, K. E. Lunsford1

    1Rutgers New Jersey Medical School, Newark, NJ, 2Houston Methodist Hospital, Houston, TX

    *Purpose: Despite stringent selection criteria for liver transplant (LT) in patients with liver-limited malignancy, post-transplant cancer recurrence remains problematic. We have previously identified a pre-LT…
  • 2022 American Transplant Congress

    The Impact of Yttium-90 Radioembolization on T Cell Phenotypes in Bridged to Transplant Hepatocellular Carcinoma Patients

    K. Nunez, T. Sandow, P. Thevenot, A. Cohen

    Ochsner Health System, New Orleans, LA

    *Purpose: Response to locoregional therapy (LRT) in hepatocellular carcinoma (HCC) impacts both progression-free survival (PFS) and bridge to transplant success. Yttrium-90 (Y90) is an effective…
  • 2022 American Transplant Congress

    Clinical Efficacy of Adjuvant Immunotherapy for Liver Transplant Recipients with Exceeding Japan Criteria of Hepatocellular Carcinoma Using Donor Liver Derived Natural Killer Cells

    M. Ohira1, Y. Imaoka2, K. Sato3, K. Imaoka1, N. Tanimine1, H. Tahara1, K. Ide1, T. Kobayashi1, Y. Tanaka1, A. G. Tzakis4, S. Nishida5, H. Ohdan1

    1Hiroshima University, Hiroshima, Japan, 2Hiroshima Uni., Hiroshima, Japan, 3Department of Gastroenterological and Transplant Surgery, Hiroshima University, Hiroshima, Japan, 4Digestive Diseases and Surgery Institute, Cleveland Clinic, Cleveland, OH, 5Univ of Miami School of Medicine, Valhalla, NY

    *Purpose: Hepatocellular carcinoma (HCC) is one of the most common cancers worldwide and is an indication for liver transplantation (LT). Immunosuppressive regimens currently used after…
  • 2022 American Transplant Congress

    Impact of MMaT Policy on Transplant for Hepatocellular Carcinoma at a Single Center

    S. Kodali1, D. W. Victor2, J. Corkrean2, A. Shetty2, C. Mobley2, M. Hobeika2, R. McMillan2, E. A. Graviss3, D. T. Nguyen3, R. McFadden4, V. Ankoma-Sey2, C. Egwim5, J. Galati2, A. Saharia2, R. M. Ghobrial2

    1Sherrie and Alan Conover Center for Liver Disease and Transplantation, Houston Methodist Hospital, Sugarland, TX, 2Sherrie and Alan Conover Center for Liver Disease and Transplantation, Houston Methodist Hospital, Houston, TX, 3Department of Pathology and Genomic Medicine, Houston Methodist Hospital, Houston, TX, 4Department of Medicine, Hepatology, Houston Methodist Hospital, Houston, TX, 5Houston Methodist Hospital, Houston, TX

    *Purpose: Hepatocellular carcinoma (HCC) is the most common primary malignant hepatic tumor. Currently, liver transplantation may be the optimal treatment for HCC. Patient selection criteria…
  • 2022 American Transplant Congress

    Induction Immunosuppression Does Not Worsen Tumor Recurrence After Liver Transplantation for T2 Hepatocellular Carcinoma and May Allow for Decreased Mortality

    C. Durkin1, T. Bittermann1, D. E. Schaubel2

    1Gastroenterology, University of Pennsylvania, Philadelphia, PA, 2Biostatistics, University of Pennsylvania, Philadelphia, PA

    *Purpose: Prior studies have suggested that induction therapy leads to worse outcomes after liver transplantation (LT) for hepatocellular carcinoma (HCC). This study evaluated the impact…
  • 2022 American Transplant Congress

    A Intention-to-Treat Analysis of 881 Consecutively Waitlisted Patients to Develop a Survival Benefit Model for Hepatocellular Carcinoma Liver Transplant Candidates

    B. V. Tran1, W. Lapisatepun1, W. Dumronggittigule1, D. Markovic2, Y. Lee1, F. Kaldas1, D. Farmer1, R. Busuttil1, V. Agopian1

    1Department of Surgery, University of California Los Angeles, Los Angeles, CA, 2Department of Medicine, Statistics Core, University of California Los Angeles, Los Angeles, CA

    *Purpose: The current liver transplantation (LT) selection paradigm for hepatocellular carcinoma (HCC) patients ignores the variable risks of waitlist dropout and post-LT recurrence/death, with the…
  • 1
  • 2
  • 3
  • …
  • 23
  • Next Page »

Visit Our Partner Sites

American Transplant Congress (ATC)

Visit the official site for the American Transplant Congress »

American Journal of Transplantation

The official publication for the American Society of Transplantation (AST) and the American Society of Transplant Surgeons (ASTS) »

American Society of Transplantation (AST)

An organization of more than 3000 professionals dedicated to advancing the field of transplantation. »

American Society of Transplant Surgeons (ASTS)

The society represents approximately 1,800 professionals dedicated to excellence in transplantation surgery. »

Copyright © 2013-2025 by American Society of Transplantation and the American Society of Transplant Surgeons. All rights reserved.

Privacy Policy | Terms of Use | Cookie Preferences